Displaying drugs 10726 - 10750 of 11741 in total
BS-001
BS-001 is a recombinant oncolytic herpes simplex virus type II (OH2) therapeutic injection (Vero cell) for human use (rHSV2hGM-CSF).
Investigational
Matched Description: … BS-001 is a recombinant oncolytic herpes simplex virus type II (OH2) therapeutic injection (Vero cell …
Petosemtamab
Petosemtamab is under investigation in clinical trial NCT03526835 (A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors).
Investigational
Matched Description: … Petosemtamab is under investigation in clinical trial NCT03526835 (A Study of Bispecific Antibody MCLA …
Pegtarviliase
Pegtarviliase is under investigation in clinical trial NCT05154890 (A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency).
Investigational
Matched Description: … Pegtarviliase is under investigation in clinical trial NCT05154890 (A Multiple Ascending Dose Study of …
Mivelsiran
Mivelsiran is under investigation in clinical trial NCT06393712 (A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy).
Investigational
Matched Description: … Mivelsiran is under investigation in clinical trial NCT06393712 (A Phase 2 Trial of ALN-APP in Patients …
5'-Guanosine-Diphosphate-Monothiophosphate
Guanosine 5'-(trihydrogen diphosphate), monoanhydride with phosphorothioic acid. A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific proto-oncogenes.
Experimental
Matched Description: … A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding …
Timdarpacept
IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG 1 fusion protein. IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome).
Investigational
Matched Description: … IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG 1 fusion protein. ... [A257261] IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With …
GSK159797
GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.
Investigational
TAFA-93
TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary...
Investigational
Matched Description: … TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical ... of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a …
SYNB1891
SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult...
Investigational
Matched Description: … cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. ... SYNB1891 is a live, modified strain of the probiotic _Escherichia coli_ Nissle engineered to produce …
Boron
Boron (B) is a chemical element with an atomic number 5 that belongs in the Period 2 and Group 13 in the periodic table. It is a low-abundant metalloid that is a poor electrical conductor at room temperature. Natural boron exists in 2 stable isotopes however pure boron is hard...
Experimental
Matched Description: … It is a low-abundant metalloid that is a poor electrical conductor at room temperature. ... Boron (B) is a chemical element with an atomic number 5 that belongs in the Period 2 and Group 13 in ... There are few pharmaceutical agents that contain a boron molecule in their structures, such as [DB09041 …
Trefoil Factor 2
The trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing proteins. They are expressed predominantly in gastric tissues with the source for them being predominantly stromal cells, although expression of TFF2 mRNA transcripts also occurs with tissue macrophages. The peptides themselves are most...
Investigational
Matched Description: … The trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing …
NasoVAX
NasoVAX contains replication-deficient adenovirus vectors in suspension. It is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial cells . Created by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses. The compound...
Investigational
Matched Description: … It is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial ... As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in ... compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a …
DG041
DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications.
DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. EP3 is a target that associates with increased risk of various vascular...
Investigational
Matched Description: … EP3 is a target that associates with increased risk of various vascular diseases. ... DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention ... DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor …
EGS21
EGS21(TM) is a beta-D-glucosylceramide (GC) compound. It is a potential therapeutic for treating immune mediated disorders. GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate drug in...
Investigational
Matched Description: … EGS21(TM) is a beta-D-glucosylceramide (GC) compound. ... It is a potential therapeutic for treating immune mediated disorders. ... GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory …
Canfosfamide
Canfosfamide is an active agent in chemotherapy-resistant ovarian cancer.
Investigational
VX-765
VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.
Investigational
Matched Description: … VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase …
Dimenoxadol
Dimenoxadol is an opioid analgesic which produces typical opioid effects such as analgesia and sedation. It is structurally similar to methadone and is a benzilic acid derivative. In the United States it is classified as a Schedule I controlled drug.
Experimental
Illicit
Matched Description: … In the United States it is classified as a Schedule I controlled drug. ... It is structurally similar to methadone and is a benzilic acid derivative. …
4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine
4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine is a solid. This compound belongs to the fluorobenzenes. These are compounds containing one or more fluorine atoms attached to a benzene ring. This substance targets the protein methionine aminopeptidase.
Experimental
Matched Description: … 4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine is a solid. ... These are compounds containing one or more fluorine atoms attached to a benzene ring. …
Trefentanil
Trefentanil (A-3665) is a fentanyl analogue opioid developed in 1992. It is more potent and shorter acting than alfentanil. Trefentanil is not used in clinics due to the severity of its respiratory depression, though it is still used in research.
Experimental
Matched Description: … Trefentanil (A-3665) is a fentanyl analogue opioid developed in 1992. …
Bempegaldesleukin
Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)).
Investigational
Matched Description: … Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination ... With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy …
CX-717
CX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.
Illicit
Investigational
Dihydromorphine
A semisynthetic analgesic used in the study of narcotic receptors. It has abuse potential. [PubChem]
Experimental
Illicit
Matched Description: … A semisynthetic analgesic used in the study of narcotic receptors. It has abuse potential. [PubChem] …
Cannabinor
Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.
Investigational
Matched Description: … Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic. …
EHC18
EHC18 is an immune regulation medicine. It is a broad spectrum of specific HCV proteins.
Investigational
Matched Description: … It is a broad spectrum of specific HCV proteins. …
FLX475
FLX475 is a small molecule CCR4 antagonist being investigated for the treatment of cancer.
Investigational
Matched Description: … FLX475 is a small molecule CCR4 antagonist being investigated for the treatment of cancer.[L9875] …
Displaying drugs 10726 - 10750 of 11741 in total